Elizabeth A. Grimm, Ph.D.

Experimental Therapeutics
University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd. Unit 0362, Y6.5318c
Houston, TX 77030
United States of America
(713) 792-3667 office

I direct a combined basic and translational laboratory focused on inflammation and selected other molecular aspects of melanoma directed toward development of novel therapeutics.  I have two major areas funded to (1) develop a nanoparticle gene therapy using a novel tumor suppressor cytokine (IL-24) and (2) test inducible nitric oxide synthase (iNOS) as a marker of poor prognosis in melanoma tumors and also as a target for therapy in project #3 of the MD Anderson SPORE in Melanoma, for which I am also the overall Director. 

The role of iNOS and other inflammatory mediators in melanoma is a major focus of current grant applications pending review. 

Three faculty actively work in my laboratory and provide mentoring on a constant basis; they also work on melanoma drug and neutraceutical development, melanoma immunity, and molecular biology of melanoma genetic subclasses.  Also, two postdoctoral fellows are studying basic molecular aspects of inflammation dysregulation in cancer.  As well, I currently support two graduate students, both from the MD/’PhD programs.  Additional grants are awarded to my laboratory personnel, so that the entire program is well funded and rich with resources to provide a thriving environment for training of MD/PhD programs.